目次

Table of Content

1. RESEARCH METHODOLOGY

2. Introduction To Antibody Drug Conjugates
2.1 Overview
2.2 Mechanism of Antibody Drug Conjugates

3. Antibody Drug Conjugates As Cancer Targeted Therapy
3.1 Applications of Antibody Drug Conjugates in Cancer
3.2 Advantages of Antibody Drug Conjugates
3.3 Comparison of Antibody Drug Conjugates With Traditional Therapies

4. Generations of Antibody Drug Conjugates
4.1 Antibody Drug Conjugates - Evolution
4.2 Next Generation Antibody Drug Conjugates Prospects

5. Commercially Approved Antibody Drug Conjugates By Brand Name, Company and Indication

6. Global Cancer Antibody Drug Conjugates Market Outlook
6.1 Current Market Scenario
6.2 Future Growth Avenues

7. Global Cancer Antibody Drug Conjugates Research and Market Trends by Region
7.1 US
7.2 China
7.3 Europe
7.4 South Korea
7.5 Australia
7.6 UK
7.7 Canada
7.8 Japan
7.9 India
7.10 Latin America

8. Global Cancer Antibody Drug Conjugates Market Trends and Development By Indications
8.1 Lung Cancer
8.2 Breast cancer
8.3 Leukemia
8.4 Ovarian Cancer
8.5 Gastrointestinal Cancers
8.6 Lymphoma
8.7 Urothelial Carcinoma
8.8 Cervical Cancer
8.9 Head and Neck Cancer
8.1 Brain Cancer
8.11 Prostate cancer
8.12 Pancreatic Cancer
8.13 Skin cancer
8.14 Esophageal cancer

9. Cancer Antibody Drug Conjugates Development Platforms By Company

10. Approved Cancer Antibody Drug Conjugates - Patent, Dosage and Price Analysis
This Chapter Gives Comprehensive Insight On Patent, Dosage and Price Analysis For 20 Approved Cancer Antibody Drug Conjugates. We Have Mentioned Few Drug Conjugates Names For Reference, Detailed Insight Included In Sample and Report 10.1 Mylotarg
10.1.1 Overview, Availability and Patent Insight
10.1.2 Pricing and Dosage Insight 10.2 Adcetris
10.2.1 Overview, Availability and Patent Insight
10.2.2 Pricing and Dosage Insight 10.3 Kadcyla
10.3.1 Overview, Availability and Patent Insight
10.3.2 Pricing and Dosage Insight 10.4 Besponsa
10.4.1 Overview and Availability Insight
10.4.2 Pricing and Dosage Insight 10.5 Lumoxiti (Market Withdrawal In 2023)
10.5.1 Overview, Availability and Patent Insight
10.5.2 Pricing and Dosage Insight 10.6 Polivy
10.6.1 Overview, Availability and Patent Insight
10.6.2 Pricing and Dosage Insight

11. Approved Cancer Antibody Drug Conjugates - Sales Insights 2020 - 2025
11.1 Adcetris
11.2 Padcev
11.3 Tivdak
11.4 Polivy
11.5 Kadcyla
11.6 Besponsa
11.7 Enhertu
11.8 Trodelvy
11.9 Zynlonta
11.10 elahere
11.11 Blenrep
11.12 Datroway

12. Global Cancer Antibody Drug Conjugates Clinical Trials Insight By Company, Country, Indication and Phase
12.1 Research
12.2 Preclinical
12.3 Phase I
12.4 Phase I/II
12.5 Phase II
12.6 Phase II/III
12.7 Phase III
12.8 Preregistration
12.9 Registration

13. Marketed Cancer Antibody Drug Conjugates Clinical Trials Insight By Company, Country, Indication and Phase

14. Cancer Antibody Drug Conjugates Combination Therapies

15. Global Cancer Antibody Drug Conjugates Market Overview
15.1 Key Market Growth Drivers
15.2 Challenges For Market Growth

16. Competitive Landscape
16.1 ADC Therapeutics
16.2 Affinity Biopharma
16.3 AstraZeneca
16.4 Biocytogen
16.5 Biokin
16.6 Bristol Myers Squibb
16.7 Daiichi Sankyo
16.8 Duality Biologics
16.9 Eli Lilly
16.10 Immunogen
16.11 Innovent Biologics
16.12 LigaChem Biosciences
16.13 Merck
16.14 Pfizer
16.15 Synaffix

List of Figures & Tables
Figure 2-1: Antibody Drug Conjugates - General Working Mechanism
Figure 3-1: Advantages of Antibody Drug Conjugates
Figure 4-1: Antibody-Drug Conjugates - Approval by Generation
Figure 4-2: Cancer Antibody Drug Conjugates - Opportunities for Next-Generation Development
Figure 6-1: Global - Cancer Antibody Drug Conjugates Market (US$ Million), 2020-2025
Figure 6-2: Global -Cancer Antibody Drug Conjugate Sales by Drug (US$ Million), H1’2025
Figure 6-3: Global - Cancer Antibody Drug Conjugate Sales by Drug (US$ Million), 2024
Figure 6-4: Global - Cancer Antibody Drug Conjugate Market Share by Drugs (%), 2024
Figure 6-5: Global - Cancer Antibody Drug Conjugate Market (US$ Million), Q1-Q4’2024
Figure 6-6: Global - Cancer Antibody Drug Conjugate Market by Drug (US$ Million), 2023
Figure 6-7: Global - Cancer Antibody Drug Conjugate Market Share by Drugs (%), 2023
Figure 6-8: Global - Cancer Antibody Drug Conjugate Market Forecast (US$ Billion), 2024 - 2031
Figure 7-1: Daiichi Sankyo DXd ADC Technology - Clinical Candidates
Figure 7-2: India - Branded v/s Biosimilar Trastuzumab Emtansine Price by Supply (US$), August’2025
Figure 8-1: REFRaME-L1 Phase 2 (NCT06555263) Study - Initiation and Completion Year
Figure 8-2: IDeate-Lung02 Phase 3 (NCT06203210) Study - Initiation and Completion Year
Figure 8-3: SGNB6A-001 Phase 1 (NCT04389632) Study - Initiation and Completion Year
Figure 8-4: SGNB6A-002 Phase 3 (NCT06012435) Study - Initiation and Completion Year
Figure 8-5: MK-2870-004 Phase 3 (NCT06074588) Study - Initiation and Completion Year
Figure 8-6: SHR-4849-101 Phase 1 (NCT06443489) Study - Initiation and Completion Year
Figure 8-7: D926QC00001 Phase 3 (NCT06112379) Study - Initiation and Completion Year
Figure 8-8: TQB2102-III-01 Phase 3 (NCT06561607) Study - Initiation and Completion Year
Figure 8-9: IZABRIGHT-Breast01 Phase 2/3 (NCT06926868) Study - Initiation and Completion Year
Figure 8-10: STARt-002 Phase 1/2 (NCT06827613) Study - Initiation and Completion Year
Figure 8-11: CA235-0001 Phase 1 (NCT06419634) Study - Initiation and Completion Year
Figure 8-12: VNC-943-101 Phase 1 (NCT06034275) Study - Initiation and Completion Year
Figure 8-13: RAINFOL-02 Phase 3 (NCT06619236) Study - Initiation and Completion Year
Figure 8-14: RAINFOL-01 Phase 1/2 (NCT05579366) Study - Initiation and Completion Year
Figure 8-15: DS6000-109 Phase 2/3 (NCT06161025) Study - Initiation and Completion Year
Figure 8-16: FONTANA Phase 1/2 (NCT05797168) Study - Initiation and Completion Year
Figure 8-17: LOXO-FRA-24001 Phase 1 (NCT06400472) Study - Initiation and Completion Year
Figure 8-18: M24-427 Phase 1 (NCT06084481) Study - Initiation and Completion Year
Figure 8-19: CUSP06-1001 Phase 1 (NCT06234423) Study - Initiation and Completion Year
Figure 8-20: TROPION-PanTumor03 Phase 2 (NCT05489211) Study - Initiation and Completion Year
Figure 8-21: IKS014-01 Phase 1 (NCT05872295) Study - Initiation and Completion Year
Figure 8-22: D9800C00001 Phase 2 (NCT06219941) Study - Initiation and Completion Year
Figure 8-23: PROCEADE-PanTumor Phase 1/2 (NCT06710132) Study - Initiation and Completion Year
Figure 8-24: CIBI343A101 Phase 1 (NCT05458219) Study - Initiation and Completion Year
Figure 8-25: CTMX-2051-101 Phase 2 (NCT06265688) Study - Initiation and Completion Year
Figure 8-26: M21-404 Phase 1 (NCT05029882) Study - Initiation and Completion Year
Figure 8-27: EBC-129-01 Phase 1 (NCT05701527) Study - Initiation and Completion Year
Figure 8-28: ADRX-0405-001 Phase 1 (NCT06710379) Study - Initiation and Completion Year
Figure 8-29: Polatuzumab Vedotin Phase 2 (NCT05410418) Study - Initiation and Completion Year
Figure 8-30: RG1122400 Phase 2 (NCT05453396) Study - Initiation and Completion Year
Figure 8-31: Blenrep Phase 2 (NCT04676360) Study - Initiation and Completion Year
Figure 8-32: Blenrep Phase 2 (NCT04676360) Study - Initiation and Completion Year
Figure 8-33: waveLINE-003 Phase 2/3 (NCT05139017) Study - Initiation and Completion Year
Figure 8-34: waveLINE-010 Phase 3 (NCT06717347) Study - Initiation and Completion Year
Figure 8-35: waveLINE-007 Phase 2 (NCT05406401) Study - Initiation and Completion Year
Figure 8-36: waveLINE-006 Phase 2 (NCT05458297) Study - Initiation and Completion Year
Figure 8-37: SUNMO Phase 3 (NCT05171647) Study - Initiation and Completion Year
Figure 8-38: NCI-2023-00999 Phase 2 (NCT05775471) Study - Initiation and Completion Year
Figure 8-39: RG1122399 Phase 2 (NCT05581589) Study - Initiation and Completion Year
Figure 8-40: BL-B01D1 Phase 2 (NCT05785039) Study - Initiation and Completion Year
Figure 8-41: 9MW2821-2023-CP301 Phase 3 (NCT06196736) Study - Initiation and Completion Year
Figure 8-42: IDE397-001 Phase 1/2 (NCT04794699) Study - Initiation and Completion Year
Figure 8-43: ADCE-T02-01 Phase 1 (NCT06597721) Study - Initiation and Completion Year
Figure 8-44: 2000023639 Phase 2 (NCT05838521) Study - Initiation and Completion Year
Figure 8-45: DESTINY-PanTumor02 Phase 2 (NCT04482309) Study - Initiation and Completion Year
Figure 8-46: 9MW2821-2021-CP102 Phase 1/2 (NCT05216965) Study - Initiation and Completion Year
Figure 8-47: ADRX-0706-001 Phase 1 (NCT06036121) Study - Initiation and Completion Year
Figure 8-48: CRB-701-01 Phase 1/2 (NCT06265727) Study - Initiation and Completion Year
Figure 8-49: SGNDV-005 Phase 2 (NCT06003231) Study - Initiation and Completion Year
Figure 8-50: EV-202 Phase 2 (NCT04225117) Study - Initiation and Completion Year
Figure 8-51: CRB-701-01 Phase 1/2 (NCT06265727) Study - Initiation and Completion Year
Figure 8-52: SGNPDL1V-001 Phase 1 (NCT05208762) Study - Initiation and Completion Year
Figure 8-53: DB-1311-O-1001 Phase 1/2 (NCT05914116) Study - Initiation and Completion Year
Figure 8-54: IRB-43179 Phase 1/2 (NCT03510208) Study - Initiation and Completion Year
Figure 8-55: MEDOPP575 Phase 2 (NCT05865990) Study - Initiation and Completion Year
Figure 8-56: UW18043 Phase 2 (NCT03725761) Study - Initiation and Completion Year
Figure 8-57: ARTEMIS-003 Phase 2 (NCT06001255) Study - Initiation and Completion Year
Figure 8-58: NCI-2021-08857 Phase 1b/2 (NCT05011188) Study - Initiation and Completion Year
Figure 8-59: IDeate-Prostate01 Phase 3 (NCT06925737) Study - Initiation and Completion Year
Figure 8-60: IDeate-PanTumor01 Phase 1/2 (NCT04145622) Study - Initiation and Completion Year
Figure 8-61: Pancreatic Ductal Adenocarcinoma - Prevalence Compared to Other Pancreatic Cancer Types
Figure 8-62: TORL2307ADC-001 Phase 1 (NCT05156866) Study - Initiation and Completion Year
Figure 8-63: EBC-129-01 Phase 1 (NCT05701527) Study - Initiation and Completion Year
Figure 8-64: XNW27011-I/II-01 Phase 1/2 (NCT06792435) Study - Initiation and Completion Year
Figure 8-65: BA3021-001 Phase 1/2 (NCT03504488) Study - Initiation and Completion Year
Figure 8-66: CP-MGC018-02 Phase 1 (NCT05293496) Study - Initiation and Completion Year
Figure 8-67: AMT-253-02 Phase 1/2 (NCT06209580) Study - Initiation and Completion Year
Figure 8-68: SGN35-033 Phase 2 (NCT04609566) Study - Initiation and Completion Year
Figure 8-69: BrUOG 413 Phase 2 (NCT05480384) Study - Initiation and Completion Year
Figure 8-70: SYSA1501-010 Phase 1/2 (NCT06577376) Study - Initiation and Completion Year
Figure 8-71: 202401158MIFD Phase 2 (NCT06329869) Study - Initiation and Completion Year
Figure 8-72: HS-20093-203 Phase 2 (NCT06112704) Study - Initiation and Completion Year
Figure 8-73: IDeate-Esophageal01 Phase 2 (NCT06644781) Study - Initiation and Completion Year
Figure 8-74: BL-B01D1-103 Phase 1 (NCT05262491) Study - Initiation and Completion Year
Figure 8-75: IPH4502-101 Phase 1 (NCT06781983) Study - Initiation and Completion Year
Figure 8-76: 9MW2821-2021-CP102 Phase 1 (NCT05216965) Study - Initiation and Completion Year
Figure 9-1: Proprietary ADC Technology - Seagen
Figure 9-2: ALE.P02 and ALE.P03 - Alentis Therapeutics
Figure 9-3: TRAAC - Tallac Therapeutics
Figure 9-4: ATAC - Heidelberg Pharma
Figure 9-5: Tub-tagandreg; and P5 - Tubulis
Figure 10-1: Mylotarg - FDA Approval, Withdrawal and Re-Approval Year
Figure 10-2: Mylotarg - Approval Year by Region
Figure 10-3: Mylotarg - Cost of 4.5 mg Supply in US (US$), July’2025
Figure 10-4: Adcetris - Approval Year by Region
Figure 10-5: US - Adcetris FDA Approval Year by Indication
Figure 10-6: Japan - Adcetris PMDA Approval Year by Indication
Figure 10-7: US - Adcetris Orphan Drug Designation Approval Year by Indication
Figure 10-8: Adcetris - Patent Expiration by Region
Figure 10-9: Adcetris - Cost of 50 mg Supply in US (US$), July’2025
Figure 10-10: US - Kadcyla FDA Approval Year by Indication
Figure 10-11: Kadcyla - Approval Year by Region
Figure 10-12: US - Kadcyla FDA Approval and Patent Expiration Year
Figure 10-13: Kadcyla - Cost of Supply in US and Europe (US$), July’2025
Figure 10-14: Kadcyla - Recommended Dose after 1st and 2nd Dose Reduction (mg/kg)
Figure 10-15: Besponsa - Approval Year by Region
Figure 10-16: Besponsa - Cost of 0.9 mg Supply in US and 1 mg Supply in Europe, July’2025
Figure 10-17: Lumoxiti - Orphan Designation Years
Figure 10-18: Lumoxiti - Patent Expiry Years
Figure 10-19: Lumoxiti - Cost of 1 mg Supply in US (US$), July’2025
Figure 10-20: Lumoxiti - Cost of 1 mg Supply in US and Europe (US$), July’2025
Figure 10-21: Polivy - Approval Year by Region
Figure 10-22: Polivy - Orphan Drug Designation Approval Year by Region
Figure 10-23: US - Polivy Orphan Drug Designation Approval and Exclusivity Year
Figure 10-24: Polivy - Cost of Supply in US and Europe (US$), July’2025
Figure 10-25: Padcev - Approval Year by Region
Figure 10-26: US - Padcev FDA Approval and Patent Expiration Year
Figure 10-27: Padcev - Cost of Supply In US and Europe (US$), July’2025
Figure 10-28: Enhertu - Approval Year by Region
Figure 10-29: US - Polivy FDA Approval Year by Indication
Figure 10-30: Enhertu - FDA Orphan Drug Designation and Exclusivity Expiration Year
Figure 10-31: Enhertu - Cost of 100 mg Supply In US and Europe (US$), July’2025
Figure 10-32: US - Trodelvy FDA Approval by Indication
Figure 10-33: Trodelvy - Approval Year by Region
Figure 10-34: Trodelvy - Patent Expiration by Region
Figure 10-35: Trodelvy - Cost of Supply In US and Europe (US$), July’2025
Figure 10-36: Blenrep - FDA and EMA Orphan Drug Designations
Figure 10-37: Blenrep - FDA and EMA Approval
Figure 10-38: Zynlonta - FDA and EMA Approval Years
Figure 10-39: Zynlonta - FDA and EMA Orphan Drug Designation Years
Figure 10-40: Zynlonta - Cost of 10 mg Supply In US and Europe (US$), July’2025
Figure 10-41: Tivdak - Cost of 40 mg Supply Europe (US$), July’2025
Figure 10-42: Ujvira - Cost of 100 mg and 160 mg Supply in India (US$), July’2025
Figure 10-43: Akalux - Sakigake Designation and PMDA Approval Year
Figure 10-44: Aidixi - China Approval Year and FDA Breakthrough Therapy Designation Year
Figure 10-45: Datroway - Cost of 100 mg Supply In US and Europe (US$), July’2025
Figure 11-1: Adcetris - Global Annual Sales (US$ Million), 2020-2025
Figure 11-2: Adcetris - Global Quarterly Sales (US$ Million), Q1 and Q2’2025
Figure 11-3: Adcetris - Global Quarterly Sales (US$ Million), Q1-Q4’2024
Figure 11-4: Padcev - Global Annual Sales (US$ Million), 2020-2025
Figure 11-5: Padcev - Global Quarterly Sales (US$ Million), Q1 and Q2’2025
Figure 11-6: Padcev - Global Quarterly Sales (US$ Million), Q1-Q4’2024
Figure 11-7: Tivdak - Global Annual Sales (US$ Million), 2021-2025
Figure 11-8: Tivdak - Global Quarterly Sales (US$ Million), Q1 and Q2’2025
Figure 11-9: Tivdak - Global Quarterly Sales (US$ Million), Q1-Q4’2024
Figure 11-10: Polivy - Global Sales Values (US$ Million), 2020-2025
Figure 11-11: Polivy - Global Quarterly Sales Values (US$ Million), Q1 and Q2’2025
Figure 11-12: Polivy - Global Sales By Region (%), H1’2025
Figure 11-13: Polivy - Global Quarterly Sales Values (US$ Million), Q1-Q4’2024
Figure 11-14: Polivy - Global Sales By Region (US$ Million), 2024
Figure 11-15: Polivy - Global Sales By Region (%), 2024
Figure 11-16: Polivy - US Annual Sales Values (US$ Million), 2020-2025
Figure 11-17: Polivy - US Quarterly Sales Values (US$ Million), Q1 and Q2’2025
Figure 11-18: Polivy - US Quarterly Sales Values (US$ Million), Q1-Q4’2024
Figure 11-19: Polivy - Europe Annual Sales Values (US$ Million), 2020-2025
Figure 11-20: Polivy - Europe Quarterly Sales Values (US$ Million), Q1 and Q2’2025
Figure 11-21: Polivy - Europe Quarterly Sales Values (US$ Million), Q1-Q4’2024
Figure 11-22: Polivy - Japan Annual Sales Values (US$ Million), 2020-2025
Figure 11-23: Polivy - Japan Quarterly Sales Values (US$ Million), Q1 and Q2’2025
Figure 11-24: Polivy - Japan Quarterly Sales Values (US$ Million), Q1-Q4’2024
Figure 11-25: Polivy - ROW Annual Sales Values (US$ Million), 2020-2025
Figure 11-26: Polivy - ROW Quarterly Sales Values (US$ Million), Q1 and Q2’2025
Figure 11-27: Polivy - ROW Quarterly Sales Values (US$ Million), Q1-Q4’2024
Figure 11-28: Kadcyla - Global Sales Values (US$ Million), 2020-2025
Figure 11-29: Kadcyla - Global Quarterly Sales Values (US$ Million), Q1 and Q2’2025
Figure 11-30: Kadcyla - Global Sales By Region (%), H1’2025
Figure 11-31: Kadcyla - Global Quarterly Sales Values (US$ Million), Q1-Q4’2024
Figure 11-32: Kadcyla - Global Sales By Region (US$ Million), 2024
Figure 11-33: Kadcyla - Global Sales By Region (%), 2024
Figure 11-34: Kadcyla - US Annual Sales Values (US$ Million), 2020-2025
Figure 11-35: Kadcyla - US Quarterly Sales Values (US$ Million), Q1 and Q2’2025
Figure 11-36: Kadcyla - US Quarterly Sales Values (US$ Million), Q1-Q4’2024
Figure 11-37: Kadcyla - Europe Annual Sales Values (US$ Million), 2020-2025
Figure 11-38: Kadcyla - Europe Quarterly Sales Values (US$ Million), Q1’2025
Figure 11-39: Kadcyla - Europe Quarterly Sales Values (US$ Million), Q1-Q4’2024
Figure 11-40: Kadcyla - Japan Annual Sales Values (US$ Million), 2020-2025
Figure 11-41: Kadcyla - Japan Quarterly Sales Values (US$ Million), Q1 and Q2’2025
Figure 11-42: Kadcyla - Japan Quarterly Sales Values (US$ Million), Q1-Q4’2024
Figure 11-43: Kadcyla - ROW Annual Sales Values (US$ Million), 2020-2025
Figure 11-44: Kadcyla - ROW Quarterly Sales Values (US$ Million), Q1 and Q2’2025
Figure 11-45: Kadcyla - ROW Quarterly Sales Values (US$ Million), Q1-Q4’2024
Figure 11-46: Besponsa - Global Annual Sales (US$ Million), 2020-2023
Figure 11-47: Besponsa - Global Sales by Region (US$ Million), 2023
Figure 11-48: Besponsa - Quarterly Sales by Region (%), Q1-Q4’2024
Figure 11-49: Besponsa - Global Quarterly Sales (US$ Million), Q1-Q4’2024
Figure 11-50: Besponsa - US Annual Sales (US$ Million), 2020-2023
Figure 11-51: Besponsa - Europe Quarterly Sales (US$ Million), 2022
Figure 11-52: Besponsa - ROW Quarterly Sales (US$ Million), 2022
Figure 11-53: Enhertu - Global Annual Sales (US$ Million), 2020-2025
Figure 11-54: Enhertu - Global Quarterly Sales Values (US$ Million), Q1 and Q2’2025
Figure 11-55: Enhertu - Global Quarterly Sales (US$ Million), Q1-Q4’2024
Figure 11-56: Trodelvy - Global Annual Sales (US$ Million), 2020-2025
Figure 11-57: Trodelvy - Global Quarterly Sales (US$ Million), Q1 and Q2’2025
Figure 11-58: Trodelvy - Annual Sales By Region (US$ Million), 2025
Figure 11-59: Trodelvy - Annual Sales By Region (%), 2025
Figure 11-60: Trodelvy - Global Quarterly Sales (US$ Million), Q1-Q4’2024
Figure 11-61: Trodelvy - Annual Sales By Region (US$ Million), 2024
Figure 11-62: Trodelvy - Annual Sales By Region (%), 2024
Figure 11-63: Trodelvy - US Annual Sales (US$ Million), 2020-2025
Figure 11-64: Trodelvy - US Quarterly Sales (US$ Million), Q1 and Q2’2025
Figure 11-65: Trodelvy - US Quarterly Sales (US$ Million), Q1-Q4’2024
Figure 11-66: Trodelvy - Europe Annual Sales (US$ Million), 2020-2025
Figure 11-67: Trodelvy - Europe Quarterly Sales (US$ Million), Q1 and Q2’2025
Figure 11-68: Trodelvy - Europe Quarterly Sales (US$ Million), Q1-Q4’2024
Figure 11-69: Trodelvy - ROW Annual Sales (US$ Million), 2022-2025
Figure 11-70: Trodelvy - ROW Quarterly Sales (US$ Million), Q1 and Q2’2025
Figure 11-71: Trodelvy - ROW Quarterly Sales (US$ Million), Q1-Q4’2024
Figure 11-72: Zynlonta - Global Annual Sales (US$ Million), 2021-2025
Figure 11-73: Zynlonta - Global Quarterly Sales (US$ Million), Q1 and Q2’2025
Figure 11-74: Zynlonta - Global Quarterly Sales (US$ Million), Q1-Q4’2024
Figure 11-75: Elahere - Global Annual Sales (US$ Million), 2022-2025
Figure 11-76: Elahere - Global Quarterly Sales (US$ Million), Q1-Q2’2025
Figure 11-77: Elahere - Global Quarterly Sales by Region (US$ Million), H2’2025
Figure 11-78: Elahere - Global Quarterly Sales (US$ Million), Q1-Q4’2024
Figure 11-79: Blenrep - Global Annual Sales (US$ Million), 2020-2025
Figure 11-80: Blenrep - Europe Quarterly Sales Value (US$ Million), Q1-Q4’2024
Figure 11-81: Datroway - Global Annual Sales (US$ Million), 2025
Figure 12-1: Global - Cancer Antibody Drug Conjugate In Clinical Trials By Phase, 2025 Till 2031
Figure 14-1: Antibody Drug Conjugate Combinations in Studies
Figure 14-2: Approved Antibody Drug Conjugate Combinations
Table 4-1: First Generation Antibody Drug Conjugates - Examples
Table 4-2: Second Generation Antibody Drug Conjugates - Examples
Table 4-3: Third Generation Antibody Drug Conjugates - Examples
Table 4-4: Fourth Generation Antibody Drug Conjugates - Examples
Table 5-1: Approved Antibody Drug Conjugates, July’2025
Table 6-1: Cancer Antibody Drug Conjugates - Recent Collaborations
Table 6-2: Cancer Antibody Drug Conjugates - Companies Securing Funding for Clinical Development
Table 6-3: Cancer Antibody Drug Conjugates - Recent Regulatory Designations
Table 6-4: Cancer Antibody Drug Conjugates - Recent IND Clearances
Table 7-1: US - Approved Cancer Antibody Drug Conjugates, May’2025
Table 7-2: China - Approved Antibody Drug Conjugates, July’2025
Table 7-3: EU - Approved Cancer Antibody Drug Conjugates, July’2025
Table 7-4: Australia - Approved Cancer Antibody Drug Conjugates, July’2025
Table 7-5: UK - Approved Antibody Drug Conjugates, July’2025
Table 7-6: Canada - Approved Cancer Antibody Drug Conjugates, July’2025
Table 7-7: Japan - Approved Cancer Antibody Drug Conjugates, July’2025
Table 8-1: Lung Cancer - Approved Antibody Drug Conjugates, July’2025
Table 8-2: Breast Cancer - Approved Antibody Drug Conjugates, July’2025
Table 8-3: Leukemia - Approved Antibody Drug Conjugates, July’2025
Table 8-4: Ovarian Cancer - Approved Antibody Drug Conjugate
Table 8-5: Gastrointestinal Cancer - Approved Antibody Drug Conjugates
Table 8-6: Lymphoma - Approved Antibody Drug Conjugates
Table 8-7: Urogenital Cancer - Approved Antibody Drug Conjugates
Table 8-8: Cervical Cancer - Approved Antibody Drug Conjugates
Table 8-9: Head and Neck Cancer - Approved Antibody Drug Conjugates
Table 10-1: Adcetris - Recommended Dosage
Table 10-2: Datroway - Premedication and Concomitant Medications
Table 10-3: Datroway - Recommended Dosage Reductions for Adverse Reactions
Table 10-4: Emrelis: Recommended Dose Reductions
Table 14-1: Antibody Drug Conjugate Combinations - Ongoing Clinical Trials